BANDO AIFA 2005;;;;;;;; Link a Progetto e CV;Codice;Responsabile Scientifico;Istituzione;Titolo;Titolo;Budget Indicato nel Contratto;"Budget Ridotto per Riduzione Numerosità Campionaria";Extra Budget Autorizzato per Farmaco o Assicurazione http://www.agenziafarmaco.gov.it/sites/default/files/1_Aiuti_Alessandro.zip;FARM5JRXRM;Aiuti Alessandro ;Fondazione Centro San Raffaele del Monte Tabor Milano;SAFETY AND EFFICACY STUDY OF GENE THERAPY WITH AUTOLOGOUS CD34+ CELLS TRANSFECTED WITH A RETROVIRAL VECTOR ENCODING THE ADENOSINE DEAMINASE (ADA) GENE (EMEA/OD/053/05) FOR THE TREATMENT OF SEVERE COMBINED IMMUNODEFICIENCY DUE TO THE LACK OF ADA;Safety And Efficacy Study Of Gene Therapy With Autologous Cd34+ Cells Transfected With A Retroviral Vector Encoding The Adenosine Deaminase (Ada) Gene (Emea/Od/053/05) For The Treatment Of Severe Combined Immunodeficiency Due To The Lack Of Ada;250.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/2_Andria_Generoso_1.zip;FARM5MATC7;Andria Generoso ;Università degli Studi di Napoli Federico II- Dip. Pediatria ;MULTICENTER STUDY OF THE EFFICACY AND TOLERABILITY OF TETRAHYDROBIOPTERIN IN A PEDIATRIC POPULATION AFFECTED BY PHENYLKETONURIA;Multicenter Study Of The Efficacy And Tolerability Of Tetrahydrobiopterin In A Pediatric Population Affected By Phenylketonuria;127.500,00;123.000,00; http://www.agenziafarmaco.gov.it/sites/default/files/3_%20Andria_Generoso_2.zip;FARM59T23W;Andria Generoso ;Università degli Studi di Napoli Federico II- Dip. Pediatria ;Efficacy and safety of treatment with N-butyl-deoxynojirimycin (NB-DNJ-miglustat) in patients with Niemann-Pick disease type C.;Efficacy And Safety Of Treatment With N-Butyl-Deoxynojirimycin (Nb-Dnj-Miglustat) In Patients With Niemann-Pick Disease Type C.;120.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/4_Beghi_Ettore.zip;FARM5LRKR9;Beghi Ettore ;Istituto di Ricerche Farmacologiche “Mario Negri” ;DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL ON THE USE OF ACETYL-L CARNITINE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS);Double-Blind Placebo-Controlled Trial On The Use Of Acetyl-L Carnitine For The Treatment Of Amyotrophic Lateral Sclerosis (Als);193.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/5_Bianchi_Maria_Luisa.zip;FARM53J37M;Bianchi Maria Luisa ;Istituto Auxologico Italiano IRCCS Milano;IMPROVING ADHERENCE TO THE ORAL THERAPY OF POST-MENOPAUSAL AND SENILE OSTEOPOROSIS WITH TARGETED INTERVENTIONS: A COMPARISON BETWEEN THE STANDARD METHOD OF MEDICAL PRESCRIPTION AND TWO METHODS CHARACTERIZED BY AN INCREASING INVOLVEMENT OF THE PATIENT;Improving Adherence To The Oral Therapy Of Post-Menopausal And Senile Osteoporosis With Targeted Interventions: A Comparison Between The Standard Method Of Medical Prescription And Two Methods Characterized By An Increasing Involvement Of The Patient;250.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/6_Caputi_Achille_Patrizio.zip;FARM5BMMH5;Caputi Achille Patrizio ;Società Italiana di Medicina Generale;EFFECTIVENESS OF COMPUTERIZED AUTOMATIC REMINDERS IN IMPROVING PHARMACOLOGICAL PRESCRIPTION IN HIGH-RISK CARDIOVASCULAR PATIENTS IN PRIMARY CARE: A CLUSTER-RANDOMIZED CONTROLLED TRIAL;Effectiveness Of Computerized Automatic Reminders In Improving Pharmacological Prescription In High-Risk Cardiovascular Patients In Primary Care: A Cluster-Randomized Controlled Trial;400.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/7_Carta_Mauro_Giovanni.zip;FARM54S73S;Carta Mauro Giovanni ;Dipartimento di Sanità Pubblica Università degliStudi di Cagliari;The use of drugs for mood disorders in Italy;The Use Of Drugs For Mood Disorders In Italy;385.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/8_Casali_Paolo_Giovanni.zip;FARM5CA5PS;Casali Paolo Giovanni ;Fondazione IRCCS Istituto Nazionale dei Tumori ;Trabectedin (ET743) in metastatic or locally advanced myxoid/round cell liposarcoma pretreated with chemotherapy;Trabectedin (Et743) In Metastatic Or Locally Advanced Myxoid/Round Cell Liposarcoma Pretreated With Chemotherapy;230.000,00;195.000,00; http://www.agenziafarmaco.gov.it/sites/default/files/9_Colao_Annamaria.zip;FARM58SK29;Colao Annamaria ;Università degli Studi di Napoli Federico II Dip. di Endocrinologia ed Oncologia Molecolare e Clinica ;EFFECTIVENESS AND TOLERABILITY OF TREATMENT WITH CABERGOLINE IN CUSHING'S SYNDROME;Effectiveness And Tolerability Of Treatment With Cabergoline In Cushing'S Syndrome;225.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/10_Comoli_Patrizia.zip;FARM55BP7R;Comoli Patrizia;Fondazione I.R.C.C.S. Policlinico “San Matteo”;USE OF ANTI-CD20 MONOCLONAL ANTIBODY (RITUXIMAB) FOR THE PREVENTION AND/OR TREATMENT OF EBV-ASSOCIATED LYMPHOPROLIFERATIVE DISEASE IN RECIPIENTS OF HEMATOPOIETIC STEM CELL AND SOLID ORGAN TRANSPLANTATION OR IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY;Use Of Anti-Cd20 Monoclonal Antibody (Rituximab) For The Prevention And/Or Treatment Of Ebv-Associated Lymphoproliferative Disease In Recipients Of Hematopoietic Stem Cell And Solid Organ Transplantation Or In Patients With Primary Immunodeficiency;150.000,00;135.000,00; http://www.agenziafarmaco.gov.it/sites/default/files/11_Corradini_Paolo.zip;FARM57EYTA;Corradini Paolo;"Fondazione IRCCS Istituto Nazionale dei Tumori ";Intensive chemo-immunotherapy as first-line treatment in adult patients with peripheral T-cell Lymphoma (PTCL);Intensive Chemo-Immunotherapy As First-Line Treatment In Adult Patients With Peripheral T-Cell Lymphoma (Ptcl);225.000,00;215.000,00; http://www.agenziafarmaco.gov.it/sites/default/files/12_Crax%C3%AC_Antonio.zip;FARM5FF44K;Craxì Antonio ;Università degli Studi di Palermo;A multicenter observational study to evaluate factors influencing efficacy, tolerance and compliance to antiviral treatment with interferon and ribavirin in chronic hepatitis C patients in daily clinical practice.;A Multicenter Observational Study To Evaluate Factors Influencing Efficacy, Tolerance And Compliance To Antiviral Treatment With Interferon And Ribavirin In Chronic Hepatitis C Patients In Daily Clinical Practice.;440.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/13_De_Placido_Sabino.zip;FARM5K3MEE;De Placido Sabino ;Università Federico II di Napoli -Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica ;FATA – First Adjuvant Trial on All aromatase inhibitors in early breast cancer. A phase 3 study comparing anastrozole, letrozole and exemestane, upfront (for 5 years) or sequentially (for 3 years after 2 years of tamoxifen), as adjuvant treatment of postmenopausal patients with endocrine-responsive breast cancer.;Fata – First Adjuvant Trial On All Aromatase Inhibitors In Early Breast Cancer. A Phase 3 Study Comparing Anastrozole, Letrozole And Exemestane, Upfront (For 5 Years) Or Sequentially (For 3 Years After 2 Years Of Tamoxifen), As Adjuvant Treatment Of Postmenopausal Patients With Endocrine-Responsive Breast Cancer.;2.700.000,00;2.420.000,00; http://www.agenziafarmaco.gov.it/sites/default/files/14_Del_Tacca_Mario.zip;FARM5YNXZM;Del Tacca Mario ;Centro Interdip. di Ricerche di Farmacologia Clinica e Terapia Sperimentale Università di Pisa, c/o Scuola Medica ;Safety and effectiveness of antidepressant treatments in general practice: an observational prospective study from the Pharmasearch network, with a Pharmacogenetic sub-study on cases of therapeutic drug failure and adverse drug reaction;Safety And Effectiveness Of Antidepressant Treatments In General Practice: An Observational Prospective Study From The Pharmasearch Network, With A Pharmacogenetic Sub-Study On Cases Of Therapeutic Drug Failure And Adverse Drug Reaction;200.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/15_Ensoli_Barbara.zip;FARM542ZYP;Ensoli Barbara ;Istituto Superiore di Sanità;Phase II Trial for the Treatment of Advanced Classical Kaposi’s Sarcoma with the HIV Protease Inhibitor Indinavir in Combination with Vinblastine/Bleomycin-based Chemotherapy;Phase Ii Trial For The Treatment Of Advanced Classical Kaposi’S Sarcoma With The Hiv Protease Inhibitor Indinavir In Combination With Vinblastine/Bleomycin-Based Chemotherapy;215.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/16_Fabbri_Leonardo.zip;FARM58J2XH;Fabbri Leonardo M. ;Università degli Studi di Modena e Reggio Emilia;COMPARISON OF A SERUM PROCALCITONIN (PRO-CT)-GUIDED TREATMENT PLAN WITH THE STANDARD GUIDELINE RECOMMENDED ANTIBIOTIC TREATMENT PLAN FOR PATIENTS HOSPITALIZED WITH A DIAGNOSIS OF EXACERBATION OF COPD;Comparison Of A Serum Procalcitonin (Pro-Ct)-Guided Treatment Plan With The Standard Guideline Recommended Antibiotic Treatment Plan For Patients Hospitalized With A Diagnosis Of Exacerbation Of Copd;700.000,00;450.000,00; http://www.agenziafarmaco.gov.it/sites/default/files/17_Fais_Stefano.zip;FARM59J4YY;Fais Stefano ;Istituto Superiore di Sanità ;PHASE II CLINICAL STUDY ON EFFICACY OF PROTON PUMP INHIBITORS PRE-TREATMENT IN OSTEOSARCOMA PATIENTS UNDERGOING CHEMOTHERAPY;Phase Ii Clinical Study On Efficacy Of Proton Pump Inhibitors Pre-Treatment In Osteosarcoma Patients Undergoing Chemotherapy;225.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/18_Falcone_Alfredo.zip;FARM5C4FB4;Falcone Alfredo ;G.O.N.O. Gruppo Oncologico Del Nord Ovest V;An open-label, multicenter, randomized phase III study of second-line chemotherapy with or without bevacizumab in metastatic colorectal cancer patients who have received first-line chemotherapy plus bevacizumab;An Open-Label, Multicenter, Randomized Phase Iii Study Of Second-Line Chemotherapy With Or Without Bevacizumab In Metastatic Colorectal Cancer Patients Who Have Received First-Line Chemotherapy Plus Bevacizumab;210.000,00;178.500,00; http://www.agenziafarmaco.gov.it/sites/default/files/19_Ferrara_Nicola.zip;FARM54J8WX;Ferrara Nicola ;Università degli Studi del Molise ;EVALUATION OF AN EDUCATIVE/INFORMATIVE STRATEGY ON DRUGS USE IN ELDERLY POPULATION WITH CHRONIC-DEGENERATIVE DISEASES IN SEVERAL CARE SETTING: A CONTROLLED RANDOMISED STUDY;Evaluation Of An Educative/Informative Strategy On Drugs Use In Elderly Population With Chronic-Degenerative Diseases In Several Care Setting: A Controlled Randomised Study;650.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/20_Filla_Alessandro.zip;FARM53XBKT;Filla Alessandro ;Università degli Studi di Napoli Federico II Dip. di Scienze Neurologiche ;Growth hormone in patients with amyotrophic lateral sclerosis as add-on therapy to Riluzole.;Growth Hormone In Patients With Amyotrophic Lateral Sclerosis As Add-On Therapy To Riluzole.;110.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/21_Gabrielli_Armando.zip;FARM5X8AWM;Gabrielli Armando ;Università Politecnica delle Marche ;Rare Diseases with microvascular involvement. High Dose Intravenous N-acetylcysteine versus Iloprost for early, rapidly progressive diffuse Systemic Sclerosis (Scleroderma);Rare Diseases With Microvascular Involvement. High Dose Intravenous N-Acetylcysteine Versus Iloprost For Early, Rapidly Progressive Diffuse Systemic Sclerosis (Scleroderma);225.000,00;170.000,00; http://www.agenziafarmaco.gov.it/sites/default/files/22_Gambacorti_Carlo.zip;FARM52NKBR;Gambacorti Carlo ;Università Milano -Bicocca;LONG TERM EFFECTS OF IMATINIB ADMINISTRATION IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS;Long Term Effects Of Imatinib Administration In Chronic Myeloid Leukemia (Cml) Patients;241.450,00;; http://www.agenziafarmaco.gov.it/sites/default/files/23_Gentili_Gilberto.zip;FARM59XAYF;Gentili Gilberto ;Azienda Sanitaria Unica Regionale (ASUR) Ancona;Evaluation of a population-based multi-modal intervention to improve the quality of cancer pain analgesic treatment;Evaluation Of A Population-Based Multi-Modal Intervention To Improve The Quality Of Cancer Pain Analgesic Treatment;640.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/24_Labianca_Roberto.zip;FARM5RWTWZ;Labianca Roberto ;Fondazione Giscad per la Ricerca sui Tumori;A randomized trial investigating the role of FOLFOX-4 regimen duration (3 versus 6 months) and bevacizumab as adjuvant therapy for patients with stage II/III colon cancer;A Randomized Trial Investigating The Role Of Folfox-4 Regimen Duration (3 Versus 6 Months) And Bevacizumab As Adjuvant Therapy For Patients With Stage Ii/Iii Colon Cancer;2.340.800,00;; http://www.agenziafarmaco.gov.it/sites/default/files/25_Lambiase_Alessandro.zip;FARM5YZTZW;Lambiase Alessandro ;Università Campus Bio-Medico Di Roma ;Multicenter, randomised, double masked, controlled studies on the efficacy of Cyclosporine eye drop treatment in preventing Vernal Keratoconjunctivitis (VKC) relapses and in treating the acute phase.;Multicenter, Randomised, Double Masked, Controlled Studies On The Efficacy Of Cyclosporine Eye Drop Treatment In Preventing Vernal Keratoconjunctivitis (Vkc) Relapses And In Treating The Acute Phase.;225.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/26_Magrini_Nicola.zip;FARM59NWKF;Magrini Nicola ;Centro per la valutazione dell’efficacia dell’Assistenza Aanitaria Azienda Unità Sanitaria Locale di Modena;Pharmacists’ outreach visits and new information formats: cluster and single-doctor randomised controlled trials for evaluating their feasibility and impact on knowledge, attitudes and prescribing practices of General Practitioners in three Italian regions;Pharmacists’ Outreach Visits And New Information Formats: Cluster And Single-Doctor Randomised Controlled Trials For Evaluating Their Feasibility And Impact On Knowledge, Attitudes And Prescribing Practices Of General Practitioners In Three Italian Regions;800.000,00;720.000,00; http://www.agenziafarmaco.gov.it/sites/default/files/27_Mannucci_Pier_Mannuccio.zip;FARM5L47XH;Mannucci Pier Mannuccio ;Fondazione Irccs Ospedale Maggiore, Mangiagalli e Regina Elena;A randomized, controlled trial to evaluate the efficacy of low-molecular-weight heparin on pregnancy outcome of women with previous pregnancy complications;A Randomized, Controlled Trial To Evaluate The Efficacy Of Low-Molecular-Weight Heparin On Pregnancy Outcome Of Women With Previous Pregnancy Complications;620.000,00;394.645,00; http://www.agenziafarmaco.gov.it/sites/default/files/28_Marchioli_Roberto.zip;FARM5T8T47;Marchioli Roberto ;Consorzio Mario Negri Sud (CMNS) ;RISCHIO ASSOLUTO CARDIOVASCOLARE - EPIDEMIOLOGIA (RIACE);Rischio Assoluto Cardiovascolare - Epidemiologia (Riace);2.000.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/29_Massacesi_Luca-Milanese_Clara.zip;FARM5RM7KL;Massacesi Luca Milanese Clara ;Fondazione Italiana Sclerosi Multipla (Fism) Onlus ;MULTICENTER RANDOMIZED CONTROLLED STUDY OF AZATHIOPRINE VERSUS INTERFERON BETA IN RELAPSING-REMITTING MULTIPLE SCLEROSIS;Multicenter Randomized Controlled Study Of Azathioprine Versus Interferon Beta In Relapsing-Remitting Multiple Sclerosis;1.470.000,00;993.100,00; http://www.agenziafarmaco.gov.it/sites/default/files/30_Mezzalira_Luigi.zip;FARM5NWAAX;Mezzalira Luigi ;Azienda ULSS n. 20 di Verona ;ITALIAN ISDB STUDY ON DEPRESSION - ISD;Italian Isdb Study On Depression - Isd;540.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/31_Naldi_Luigi.zip;FARM5SC2J5;Naldi Luigi ;Centro Studi Gised OO.R. – USC Dermatologia ;Establishment of a European surveillance network to assess the long term effectiveness and safety of biological agents, i.e., Tumor Necrosis Factor alpha (TNF-alpha) antagonists and T cell targeted molecules, in the treatment of psoriasis with particular attention to the risk of rare events;Establishment Of A European Surveillance Network To Assess The Long Term Effectiveness And Safety Of Biological Agents, I.E., Tumor Necrosis Factor Alpha (Tnf-Alpha) Antagonists And T Cell Targeted Molecules, In The Treatment Of Psoriasis With Particular Attention To The Risk Of Rare Events;320.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/32_Nicolucci_Antonio.zip;FARM57W8MN;Nicolucci Antonio ;Consorzio Mario Negri Sud ;A randomized, placebo-controlled study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. (ACCEPT-D: Aspirin and simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes);A Randomized, Placebo-Controlled Study Of The Efficacy Of Low-Dose Aspirin In The Prevention Of Cardiovascular Events In Subjects With Diabetes Mellitus Treated With Statins. (Accept-D: Aspirin And Simvastatin Combination For Cardiovascular Events Prevention Trial In Diabetes);2.700.000,00;1.950.000,00; http://www.agenziafarmaco.gov.it/sites/default/files/33_Nobili_Bruno.zip;FARM5JJASJ;Nobili Bruno ;Dipartimento di Pediatria, Seconda Università degli Studi di Napoli ;A randomized, open-label therapeutic trial for the evaluation of the efficacy and safety of Neridronate (Nerixia) in the treatment of osteoporosis in patients with Thalassemia Major and Severe Thalassemia Intermedia.;A Randomized, Open-Label Therapeutic Trial For The Evaluation Of The Efficacy And Safety Of Neridronate (Nerixia) In The Treatment Of Osteoporosis In Patients With Thalassemia Major And Severe Thalassemia Intermedia.;205.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/34_Panei_Pietro.zip;FARM5AJL82;Panei Pietro ;Istituto Superiore di Sanità;Long term safety of the drugs used in the treatment of school-aged children with attention deficit/hyperactivity disorder and epidemiology of the disease in the Italian population.;Long Term Safety Of The Drugs Used In The Treatment Of School-Aged Children With Attention Deficit/Hyperactivity Disorder And Epidemiology Of The Disease In The Italian Population.;500.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/35_Parenti_Giancarlo.zip;FARM5S3JT5;Parenti Giancarlo ;Università degli Studi di Napoli Dip. di Pediatria;EVALUATION OF THE EFFICACY OF THE TREATMENT WITH ACE-INHIBITORS ON THE RENAL DAMAGE IN PATIENTS AFFECTED BY GLYCOGEN STORAGE DISEASE TYPE 1a AND TYPE 1b AND OF THE VITAMIN E ON NEUTROPENIA OF PATIENTS WITH GLYCOGEN STORAGE DISEASE 1b;Evaluation Of The Efficacy Of The Treatment With Ace-Inhibitors On The Renal Damage In Patients Affected By Glycogen Storage Disease Type 1A And Type 1B And Of The Vitamin E On Neutropenia Of Patients With Glycogen Storage Disease 1B;146.000,00;124.295,00; http://www.agenziafarmaco.gov.it/sites/default/files/36_Pareyson_Davide.zip;FARM53APAH;Pareyson Davide ;Fondazione IRCCS di Rilievo Nazionale –Istituto Nazionale Neurologico C. Besta ;MULTICENTRE RANDOMISED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF LONG-TERM ASCORBIC ACID TREATMENT IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A (CMT-TRIAAL: CMT-TRial Italian with Ascorbic Acid Long term);Multicentre Randomised Double Blind Placebo Controlled Trial Of Long-Term Ascorbic Acid Treatment In Charcot-Marie-Tooth Disease Type 1A (Cmt-Triaal: Cmt-Trial Italian With Ascorbic Acid Long Term);140.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/37_Perico_Norberto.zip;FARM5PWB9L;Perico Norberto ;Istituto di Ricerche Farmacologiche Mario Negri ;A RANDOMIZED, PROSPECTIVE, MULTICENTER TRIAL TO COMPARE THE EFFECT ON CHRONIC ALLOGRAFT NEPHROPATHY OF MYCOPHENOLATE MOFETIL VERSUS AZATHIOPRINE AS THE SOLE IMMUNOSUPPRESSIVE THERAPY FOR KIDNEY TRANSPLANT RECIPIENTS;A Randomized, Prospective, Multicenter Trial To Compare The Effect On Chronic Allograft Nephropathy Of Mycophenolate Mofetil Versus Azathioprine As The Sole Immunosuppressive Therapy For Kidney Transplant Recipients;540.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/38_Perna_Alessandra.zip;FARM5XWMZ4;Perna Alessandra Fortunata Rossana ;Centro Interdipartimentale di Ricerca Clinica, Seconda Università degli Studi di Napoli ;Therapy of hyperhomocysteinemia in hemodialysis patients: effects of acetylcysteine and folates;Therapy Of Hyperhomocysteinemia In Hemodialysis Patients: Effects Of Acetylcysteine And Folates;170.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/39_Perucca_Emilio.zip;FARM52K2WM;Perucca Emilio ;Università degli Studi di Pavia Dip. di Medicina Interna e Terapia Medica ;A PROSPECTIVE STUDY ON LONG-TERM OUTCOME AND POTENTIAL USEFULNESS OF AN INTERVENTION AIMED AT REDUCING ADVERSE EFFECTS IN PATIENTS WITH REFRACTORY EPILEPSY Coordinator: Emilio Perucca, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy* Steering Committee Members: E. Perucca (Pavia), A. Baruzzi (Bologna), G.B. De Sarro (Catanzaro);A Prospective Study On Long-Term Outcome And Potential Usefulness Of An Intervention Aimed At Reducing Adverse Effects In Patients With Refractory Epilepsy Coordinator: Emilio Perucca, Department Of Internal Medicine And Therapeutics, University Of Pavia, Pavia, Italy* Steering Committee Members: E. Perucca (Pavia), A. Baruzzi (Bologna), G.B. De Sarro (Catanzaro);530.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/40_Remuzzi_Giuseppe.zip;FARM55L9BE;Remuzzi Giuseppe ;Istituto di Ricerche Farmacologiche Mario Negri;A PROSPECTIVE, RANDOMIZED, OPEN LABEL BLINDED END POINT (PROBE) TRIAL TO EVALUATE WHETHER, AT COMPARABLE BLOOD PRESSURE CONTROL, COMBINED THERAPY WITH THE ACE INHIBITOR BENAZEPRIL AND THE ANGIOTENSIN II RECEPTOR BLOCKER (ARB) VALSARTAN REDUCES PROGRESSION TO ESRD MORE EFFECTIVELY THAN BENAZEPRIL OR VALSARANT ALONE IN HIGH RISK PATIENTS WITH TYPE 2 DIABETES AND OVERT NEPHROPATHY (VALID STUDY);A Prospective, Randomized, Open Label Blinded End Point (Probe) Trial To Evaluate Whether, At Comparable Blood Pressure Control, Combined Therapy With The Ace Inhibitor Benazepril And The Angiotensin Ii Receptor Blocker (Arb) Valsartan Reduces Progression To Esrd More Effectively Than Benazepril Or Valsarant Alone In High Risk Patients With Type 2 Diabetes And Overt Nephropathy (Valid Study);490.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/41_Rizzetto_Mario.zip;FARM537A8L;Rizzetto Mario ;Dip. Medicina Interna Università di Torino ;Study of the use in Italy in routine clinical practice of Pegylated Interferons for the therapy of chronic hepatitis C. Proposed by the Società Italiana di Gastroenterologia (SIGE), the Istituto Superiore di Sanità (ISS), the Associazione Italiana dei Gastroenterologi Ospedalieri (AIGO), the Associazione Italiana Studio Fegato (AISF), the Società Italiana di Malattie Infettive e Tropicali (SIMIT).;Study Of The Use In Italy In Routine Clinical Practice Of Pegylated Interferons For The Therapy Of Chronic Hepatitis C. Proposed By The Società Italiana Di Gastroenterologia (Sige), The Istituto Superiore Di Sanità (Iss), The Associazione Italiana Dei Gastroenterologi Ospedalieri (Aigo), The Associazione Italiana Studio Fegato (Aisf), The Società Italiana Di Malattie Infettive E Tropicali (Simit).;700.000,00;665.000,00; http://www.agenziafarmaco.gov.it/sites/default/files/42_Ruggenenti_Piero.zip;FARM5TPY8X;Ruggenenti Piero ;Istituto di Ricerche Farmacologiche Mario Negri ;A PROSPECTIVE, RANDOMIZED, OPEN LABEL BLINDED END POINT (PROBE) TRIAL TO EVALUATE WHETHER, AT COMPARABLE BLOOD PRESSURE CONTROL, COMBINED THERAPY WITH THE ACE INHIBITOR BENAZEPRIL AND THE ANGIOTENSIN II RECEPTOR BLOCKER (ARB) VALSARTAN, REDUCES THE INCIDENCE OF MICROALBUMINURIA MORE EFFECTIVELY THAN BENAZEPRIL OR VALSARTAN ALONE IN HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES AND HIGH-NORMAL ALBUMINURIA(VARIETY STUDY);A Prospective, Randomized, Open Label Blinded End Point (Probe) Trial To Evaluate Whether, At Comparable Blood Pressure Control, Combined Therapy With The Ace Inhibitor Benazepril And The Angiotensin Ii Receptor Blocker (Arb) Valsartan, Reduces The Incidence Of Microalbuminuria More Effectively Than Benazepril Or Valsartan Alone In Hypertensive Patients With Type 2 Diabetes And High-Normal Albuminuria(Variety Study);1.950.000,00;1.643.180,00; http://www.agenziafarmaco.gov.it/sites/default/files/43_Ruperto_Nicolino.zip;FARM52EBT5;Ruperto Nicolino ;Irccs Istituto G. Gaslini;Phase II effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine a versus prednisone plus methotrexate;Phase Ii Effectiveness Randomised Actively Controlled Clinical Trial In New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine A Versus Prednisone Plus Methotrexate;230.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/44_Samani_Fabio.zip;FARM5KZ4NJ;Samani Fabio ;Presidente Società Italiana di Medicina Generale ;Evaluation of prescribing pattern and safety profile of antidepressant and antipsychotic medications in Italian general practice;Evaluation Of Prescribing Pattern And Safety Profile Of Antidepressant And Antipsychotic Medications In Italian General Practice;380.000,00;365.000,00; http://www.agenziafarmaco.gov.it/sites/default/files/45_Santoro_Armando.zip;FARM5P8YFC;Santoro Armando ;Regione Lombardia Direzione Generale Sanità ;TOP TRIAL: A RANDOMIZED CLINICAL TRIAL OF TRASTUZUMAB (HERCEPTIN®) OPTIMIZATION IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER OVEREXPRESSING HER2 AFTER A FIRST-LINE CHEMOTHERAPY PLUS TRASTUZUMAB.;Top Trial: A Randomized Clinical Trial Of Trastuzumab (Herceptin®) Optimization In Patients With Locally Advanced And/Or Metastatic Breast Cancer Overexpressing Her2 After A First-Line Chemotherapy Plus Trastuzumab.;520.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/46_Scroccaro_Giovanna.zip;FARM5N5MZT;Scroccaro Giovanna ;Azienda Ospedaliera Istituti Ospitalieri di Verona;PROPHYLACTIC PRESCRIPTION OF LOW MOLECULAR WEIGHT HEPARIN IN THE ORTHOPAEDIC SURGICAL SETTING: IMPACT OF REGIONAL GUIDELINES;Prophylactic Prescription Of Low Molecular Weight Heparin In The Orthopaedic Surgical Setting: Impact Of Regional Guidelines;175.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/47_Strippoli_Giovanni.zip;FARM537JNE;Strippoli Giovanni ;Consorzio Mario Negri Sud ;CARDIO-RENAL EFFECTS OF RENIN ANGIOTENSIN SYSTEM INHIBITION IN CARDIO-RENAL RISK PATIENTS: COMPARATIVE RANDOMIZED TRIAL OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS, ANGIOTENSIN RECEPTOR BLOCKERS OR THEIR COMBINATION IN PATIENTS WITH ONE OR MORE CARDIOVASCULAR RISK FACTORS, SCREEN POSITIVE FOR ALBUMINURIA OR PROTEINURIA, DIABETIC OR NOT DIABETIC. THE CARDIO-RENAL PROTECTION TRIAL.;Cardio-Renal Effects Of Renin Angiotensin System Inhibition In Cardio-Renal Risk Patients: Comparative Randomized Trial Of Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers Or Their Combination In Patients With One Or More Cardiovascular Risk Factors, Screen Positive For Albuminuria Or Proteinuria, Diabetic Or Not Diabetic. The Cardio-Renal Protection Trial.;2.250.000,00;1.819.800,00; http://www.agenziafarmaco.gov.it/sites/default/files/48_Tabolli_Stefano.zip;FARM5HS35J;Tabolli Stefano ;Istituto Dermopatico dell'Immacolata, (IDI) – IRCCS ;EVALUATION OF THE IMPACT OF WRITING EXERCISES AND EDUCATIONAL INTERVENTIONS ON QUALITY OF LIFE, USE OF HEALTH RESOURCES, AND ADHERENCE TO TREATMENT IN PATIENTS WITH PSORIASIS;Evaluation Of The Impact Of Writing Exercises And Educational Interventions On Quality Of Life, Use Of Health Resources, And Adherence To Treatment In Patients With Psoriasis;323.400,00;274.890,00; http://www.agenziafarmaco.gov.it/sites/default/files/49_Tagliavini_Fabrizio.zip;FARM573ME8;Tagliavini Fabrizio ;Fondazione IRCCS di Rilievo Nazionale Istituto Nazionale Neurologico C. Besta ;A randomized, double-blind pilot study versus placebo for the evaluation of the efficacy of doxycycline administered by oral route in patients affected by Creutzfeldt-Jakob disease.;A Randomized, Double-Blind Pilot Study Versus Placebo For The Evaluation Of The Efficacy Of Doxycycline Administered By Oral Route In Patients Affected By Creutzfeldt-Jakob Disease.;230.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/50_Todesco_Silvano.zip;FARM5KJ9P5;Todesco Silvano ;Università degli Studi di Padova Dipartimento di Medicina Clinica e Sperimentale ;The risk/benefit profile of biologic agents in real-world rheumatology and dermatology practice;The Risk/Benefit Profile Of Biologic Agents In Real-World Rheumatology And Dermatology Practice;465.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/51_Trimarco_Bruno.zip;FARM5STRH9;Trimarco Bruno ;Dip. di Medicina Clinica Scienze Cardiovascolari ed Immunologiche, Università Federico II ;Improvement of persistance and adherence to diuretic treatment as first choice for hypertension: a study of active pharmacovigilance and pharmacogenetics. (Area 3);Improvement Of Persistance And Adherence To Diuretic Treatment As First Choice For Hypertension: A Study Of Active Pharmacovigilance And Pharmacogenetics. (Area 3);1.350.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/52_Viegi_Giovanni.zip;FARM5JYS5A;Viegi Giovanni ;Istituto di Fisiologia Clinica Consiglio Nazionale delle Ricerche (CNR) ;Respiratory allergic diseases: monitoring study of GINA and ARIA guidelines (ARGA).;Respiratory Allergic Diseases: Monitoring Study Of Gina And Aria Guidelines (Arga).;1.700.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/53_Volterrani_Maurizio.zip;FARM59BN99;Volterrani Maurizio ;Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Pisana;Evaluation of tolerability and efficacy of the combination Sildenafil/Bosentan in patients with severe pulmonary hypertension;Evaluation Of Tolerability And Efficacy Of The Combination Sildenafil/Bosentan In Patients With Severe Pulmonary Hypertension;380.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/54_Zanchetti_Alberto.zip;FARM5JYE9K;Zanchetti Alberto ;Istituto Auxologico Italiano IRCCS Milano;PHIDIAS - Prevention of Hypertension Incidence and Diabetes Italian Assessment Study Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects with Metabolic Syndrome and High-Normal Blood Pressure;Phidias - Prevention Of Hypertension Incidence And Diabetes Italian Assessment Study Therapeutic Strategies Of Prevention Of Diabetes And Hypertension In Subjects With Metabolic Syndrome And High-Normal Blood Pressure;2.000.000,00;;